Start here
Tapinarof is the first genuinely new topical for psoriasis in years, and what makes it useful is that there is no steroid clock — I treat the face, eyelids, groin and under the breasts without counting weeks. The catch is folliculitis: about one in five people in the trials got small red bumps where they applied it, mostly mild, so I warn people up front rather than letting it be a surprise. Judge it at twelve weeks, not two. In the long-term study, many people who cleared completely stayed clear for months after stopping — I cannot say that about a steroid.
— Dr. Schwarz, Board Certified Dermatologist
Key Facts
−
| Also called | Vtama, benvitimod |
| Drug class | Topical aryl hydrocarbon receptor agonist, non-steroidal |
| Applied as | 1% cream |
| Typical course | Until clear, then stopped and restarted if psoriasis returns |
| Time to work | Some change by 4 weeks, judged at 12 weeks |
| Prescription only | Yes |
What It Is
−
Tapinarof is a prescription cream approved in 2022 for plaque psoriasis in adults, and later for eczema in children and adults. It is not a steroid and not a vitamin D analog — it works through a completely different route inside the skin cell. The molecule is small, related to the stilbenes found in plants, and made synthetically. Because it is not a steroid, there is no limit on how long it can be used and no skin thinning, so it goes on the face, eyelids, armpits, groin and under the breasts.
How It Works
−
Skin cells carry a switch called the aryl hydrocarbon receptor, or AhR. It reads certain small molecules and, when switched on, changes which genes the cell reads. Tapinarof switches it on deliberately.
Two things follow. The overactive inflammation behind plaque psoriasis, the interleukin-17 pathway, is turned down. And the genes that build the skin's outer barrier, including filaggrin and loricrin, are turned back up — which is why skin often feels less rough and less scaly before the redness goes.
Switching on AhR also raises the cell's own antioxidant response, reducing the oxidative stress found in plaques. A calmer immune signal plus a rebuilt barrier is the likely reason some people stay clear for a while after stopping instead of flaring straight back.
Here is where Tapinarof acts in the skin, and what the others do instead.
About Tapinarof
Compare
Skin basics
In a plaque, skin cells travel from the bottom of the epidermis to the surface in four to six days instead of a month, and pile up as scale. Tapinarof slows them back down, so the plaque thins. A newer cream, no steroid, and the clear time after stopping is longer than with most.
Tapinarof is small and fat-soluble and crosses well. Folliculitis is its most common side effect, which is what getting in easily looks like on some skin.
The redness, swelling and itch are the immune system reacting, not the damage itself. This turns that reaction down where it is happening, in the skin, which is why a rash settles within days.
The outer film of dead cells and oil. It holds water in and keeps irritants out, and it is thinner than a sheet of paper. Almost every dry, itchy, stinging skin problem starts here.
The outer layer, and the only one anything in a jar reaches. It renews itself constantly: a cell made at the bottom takes about a month to reach the surface and flake off. Most of what a skincare product does, it does here.
The living layer underneath, holding the blood vessels, the nerves and the collagen. It is where lasting change happens and it is hard to reach: most of what is sold for the skin never gets this far.
What It Treats
−


Not the Best For
−
Forms
−
One form, and it goes everywhere on the body.
Cream, 1%:
Strengths
−
One strength. Nothing to start low on, nothing to escalate to.
Basics
−
Sample Routine
−
Here is where Tapinarof sits in a day, and what goes around it. Pick what you are treating and what your skin is like, and the rest of the routine changes to suit.
What to Expect
−
What to Avoid
−
- Getting it in the eyes or mouth Approved on the face and eyelid skin, but not in the eye. Rinse with water if it gets there.
- Applying it thickly to hair-bearing areas More cream does not work better and appears to make folliculitis more likely. A thin layer is the instruction.
- Plastic wrap or airtight dressings Occluding it was not studied and pushes more drug in than intended.
- Broken, weeping or cracked skin Wait for it to close over. Anything applied to open skin stings more and is absorbed more.
- Assuming a new rash is just dryness A rash where you applied it may be contact dermatitis. An itchy rash confined to the treated areas is worth having looked at.
Monitoring
−
No blood tests are required. There is nothing to check on a lab report, which is one of the practical arguments for a topical over a tablet.
Monitoring is a look at the skin and a conversation, usually at about twelve weeks. Two things get asked about: folliculitis, and whether it is a few bumps or enough to be a problem; and whether the treated skin has become itchy and inflamed in a new way, which points to contact dermatitis rather than psoriasis.
Long term there is no organ risk to track and no skin thinning to watch for, so there is no maximum duration. What is genuinely not known yet is what many years of continuous use looks like, because the drug is recent. A common pattern is to treat until clear, stop, and restart when plaques come back.
If You Stop
−
No taper and no withdrawal. Stopping abruptly is normal. The difference from a steroid is that psoriasis does not usually flare worse than before when the cream stops. In the long-term extension study, people who reached completely clear skin came off treatment and a large share stayed clear for months, with the average off-treatment period running several months. When plaques come back, restart the cream. It generally works again.
Cost
−
Brand only, with no generic. It is one of the more expensive topicals for psoriasis and costs far more than a generic steroid or generic calcipotriene. Coverage varies and prior authorization is common; plans frequently want to see a topical steroid, and often a vitamin D analog, tried first. Manufacturer copay cards exist and the terms change, so check the current one. Because a tube covers only so much, cost climbs quickly with widespread psoriasis, which is one of the main reasons people end up on a tablet or injection instead.
Ask Your Doctor
−
How It Compares
−






Myths
+
- "It is a steroid cream." It is not, and it does not touch the steroid receptor. That is why there is no weekly limit, no skin thinning, and no restriction on the face or skin folds.
- "The folliculitis means it is infected." Usually not. It is irritation of the hair follicle where the cream went, it is usually mild, and most people in the trials kept using the drug through it. An antibiotic is not the automatic answer.
- "It cures psoriasis." It clears plaques. Psoriasis is a long-term condition and it can come back. What is unusual is that some people get months off treatment before it does.
- "You cannot use it with anything else." It is regularly used alongside moisturizers, and doctors combine it with other psoriasis treatments, including phototherapy and systemic drugs.
- "It makes you sun-sensitive." There is no known photosensitivity from tapinarof. Sunlight often helps psoriasis, and sun protection is still worth doing for other reasons.
Questions Patients Ask
+
Is it a steroid?
No. It works on a different switch inside the skin cell, the aryl hydrocarbon receptor. That is why there is no time limit and no skin thinning.
Can I put it on my face?
Yes — approved for the face and skin folds, one of its main advantages over a steroid.
What are the little bumps I am getting?
Most likely folliculitis — small red bumps around hair follicles where you applied it. The most common side effect in the trials, at roughly one in five people, usually mild, and most carried on.
How long before I know if it works?
Give it twelve weeks. Some change usually shows by four.
Can I stop once I am clear?
That is a normal way to use it. In the long-term study, many who cleared completely stayed clear for months, then restarted when plaques returned.
Does it work for eczema too?
Yes, it is also approved for atopic dermatitis, in adults and in children from age two.
References
+
- Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. Journal of the American Academy of Dermatology. 2025. — Journal of the American Academy of Dermatology, 2025
- Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology. 2026. — Journal of the American Academy of Dermatology, 2026
- Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. The Cochrane database of systematic reviews. 2024. — The Cochrane database of systematic reviews, 2024
- Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. The New England journal of medicine. 2021. — The New England journal of medicine, 2021
- Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. Journal of the American Academy of Dermatology. 2024. — Journal of the American Academy of Dermatology, 2024
- Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. Journal of the American Academy of Dermatology. 2025. — Journal of the American Academy of Dermatology, 2025
